「テスト」の版間の差分

提供：脳科学辞典
ナビゲーションに移動 検索に移動
細編集の要約なし
細編集の要約なし
 
(2人の利用者による、間の121版が非表示)
1行目: 1行目:
==Brodmann areas for human & non-human primates==
{| class="wikitable"
 
!化合物!!ClinicalTrials.gov Identifier !! 年 !! 国 !! 対象疾患 !! Phase !! 結果
 
|-
* [[Brodmann areas 3, 1 and 2|ブロードマン3、1、2野 - 一次体性感覚野]] (frequently referred to as Areas 3, 1, 2 by convention)
| Taltirelin Hydrate || [https://www.clinicaltrials.gov/ct2/show/NCT04107740 NCT04107740] || 2019- || 韓国 || SCD全般 || 4 || 現在進行中
* [[Brodmann area 4|ブロードマン4野 – 一次運動野]]
|-
* [[Brodmann area 5|ブロードマン5野 – 体性感覚連合野]]
| KPS-0373(Rovatirelin) || [https://www.clinicaltrials.gov/ct2/show/NCT01970098 NCT01970098] || 2013-2015 || 日本 || 軽度～中等度のSCD || 3 || [https://jnnp.bmj.com/content/91/3/254 部分的に有効]
* [[Brodmann area 6|ブロードマン6野]] - [[前運動野]] 、補足運動野
|-
* [[Brodmann area 7|ブロードマン7野 -体性感覚連合野]]]
| Riluzole || [https://www.clinicaltrials.gov/ct2/show/NCT03347344?cond=Spinocerebellar+Degeneration&draw=3&rank=11 NCT03347344] || 2018-2019 || フランス || SCA2 || 3 || 不明
* [[Brodmann area 8|ブロードマン8野]] - [[前頭眼野]]
|-
* [[Brodmann area 9|ブロードマン9野]] - [[前頭前野背外側部]]
| Transcranial Magnetic Stimulation || [https://www.clinicaltrials.gov/ct2/show/NCT03347344 NCT01975909] || 2013-2016 || 米国 || genetically-confirmed SCA || Not Applicable || 有効性なし
* [[Brodmann area 10|ブロードマン10野]] - [[前頭極]]
|-
* [[Brodmann area 11|ブロードマン11野]] - [[眼窩前頭野]]
| Lithium Carbonate || [https://www.clinicaltrials.gov/ct2/show/NCT00683943 NCT00683943] || 2008－2010 || 米国 || SCA1 || 1 ||
* [[Brodmann area 12|ブロードマン12野]] - [[眼窩前頭野]]
|-
* [[Brodmann area 13|ブロードマン13野]] and [[Brodmann area 14|ブロードマン14野]]<sup>*</sup> - [[島皮質]]
| Intravenous Immune Globulin || [https://www.clinicaltrials.gov/ct2/show/NCT02287064 NCT02287064] || 2015－2016 || 米国 || SCA types 1, 2, 3, 6, 10, or 11 || 1 || まだ発表なし
* [[Brodmann area 15|ブロードマン15野]]<sup>*</sup> - Anterior Temporal Lobe
|-
* [[Brodmann area 17|ブロードマン17野]] - [[Visual_cortex#V1|一次視覚野 (V1)]]
| Oral Trehalose || [https://www.clinicaltrials.gov/ct2/show/NCT04399265 NCT04399265] || 2020ー- || マレーシア || Genetically confirmed SCA 3 || Not Applicable || 進行中
* [[Brodmann area 18|ブロードマン18野]] - [[Visual_cortex#V2|二次視覚野(V2)]]]
|-
* [[Brodmann area 19|ブロードマン19野]] - [[Visual_cortex#V3|視覚連合野(V3)]]
| Varenicline (Chantix®) || [https://www.clinicaltrials.gov/ct2/show/NCT00992771 NCT00992771] || 2009－2012 || 米国 || SCA3 || 2 || [https://n.neurology.org/content/78/8/545.long 有効]
* [[Brodmann area 20|ブロードマン20野]] - [[下側頭回]]
|-
* [[Brodmann area 21|ブロードマン21野]] - [[中側頭回]]
| Umbilical Cord Mesenchymal Stem Cells || [https://www.clinicaltrials.gov/ct2/show/NCT03378414 NCT03378414] || 2017－ || 中国 || SCA1,2,4,6 || 2 || 詳細不明
* [[Brodmann area 22|ブロードマン22野]] - [[上側頭回]]
|-
* [[Brodmann area 23|ブロードマン23野]] - 腹側[[後帯状皮質]]
| Troriluzole || [https://www.clinicaltrials.gov/ct2/show/NCT02960893 NCT03701399] || 2018－ || 米国 || SCA1,2,3,6,7,8,10 || 2，3 || 進行中
* [[Brodmann area 24|ブロードマン24野]] - 腹側[[前帯状皮質]]
|-
* [[Brodmann area 25|ブロードマン25野]] – [[膝下野]]
| Sodium Phenylbutyrate || [https://www.clinicaltrials.gov/ct2/show/NCT01096095 NCT01096095] || 2010－2012 || ブラジル || SCA3 || 2 || 中止
* [[Brodmann area 26|ブロードマン26野]] - [[Ectosplenial_area_26|Ectosplenial]] portion of the retrosplenial region of the cerebral cortex
|-
* [[Brodmann area 27|ブロードマン27野]] - [[梨状葉皮質]]
| Dalfampridine || [https://www.clinicaltrials.gov/ct2/show/NCT01811706 NCT01811706] || 2013－2015 || 米国 || SCA1,2,3,6 || Not Applicable || 有効性なし
* [[Brodmann area 28|ブロードマン28野]] - [[後嗅内皮質]]
|-
* [[Brodmann area 29|ブロードマン29野]] - [[脳梁膨大後部帯状皮質]]
| CAD-1883 || [https://www.clinicaltrials.gov/ct2/show/NCT04301284 NCT04301284] || 2020－ || 米国 || SCA1,2,3,6,7,10,17 || 2 || 延期(COVID-19のため
* [[Brodmann area 30|ブロードマン30野]] - [[帯状皮質]]の一部
|-
* [[Brodmann area 31|ブロードマン31野]] - [[背側後帯状皮質]]
| Docosahexaenoic Acid (DHA) || [https://www.clinicaltrials.gov/ct2/show/NCT03109626 NCT03109626] || 2015－2018 || イタリア || SCA38 || Not Applicable || [https://onlinelibrary.wiley.com/doi/full/10.1002/ana.25059 有効]
* [[Brodmann area 32|ブロードマン32野]] - [[背側前帯状皮質]]
|-
* [[Brodmann area 33|ブロードマン33野]] - [[前帯状皮質]]の一部
| Stemchymal® || [https://www.clinicaltrials.gov/ct2/show/NCT02540655 NCT02540655] || 2015－ || 台湾 || SCA2,3 || 2 || 不明
* [[Brodmann area 34|ブロードマン34野]] - [[前嗅内皮質]] (on the [[海馬傍回]])
|-
* [[Brodmann area 35|ブロードマン35野]] - [[嗅周囲皮質]] (on the [[海馬傍回]])
| Intravenous Cabaletta || [https://www.clinicaltrials.gov/ct2/show/NCT02147886 NCT02147886] || 2014-2016 || イスラエル || SCA3 || 2 || 結果？
* [[Brodmann area 36|ブロードマン36野]] - [[海馬傍回皮質]] (on the [[海馬傍回皮質]])
|-
* [[Brodmann area 37|ブロードマン37野]] - [[紡錘状回]]
| Coenzyme Q10 || [https://www.clinicaltrials.gov/ct2/show/NCT00957216 NCT00957216] || 2009－2018 || 米国 || 弧発性SCD || 1 || 結果？
* [[Brodmann area 38|ブロードマン38野]] - [[側頭極]]  
|-
* [[Brodmann area 39|ブロードマン39野]] - [[角回]]
| BHV-4157 || [https://clinicaltrials.gov/ct2/show/NCT03408080 NCT03408080] || 2018－ || 米国 || SCA1,2,3,6 || 3 || エントリー中止中
* [[Brodmann area 40|ブロードマン40野]] - [[縁上回]]  
|-
* [[Brodmann area 41 & 42|ブロードマン41、42野 - 一次聴覚野]]
| Vatiquinone || [https://www.clinicaltrials.gov/ct2/show/NCT04577352 NCT04577352] || 2020－ || 米国 || Friedreich Ataxia || 2，3 || 開始前
* [[Brodmann area 43|ブロードマン43野]] - Primary gustatory cortex
|-
* [[Brodmann area 44|ブロードマン44野]] - [[下前頭回]][[弁蓋部]]
| CTI-1601 || [https://www.clinicaltrials.gov/ct2/show/NCT04519567 NCT04519567] || 2020－ || 米国 || Friedreich Ataxia || 1 || 開始前
* [[Brodmann area 45|ブロードマン45野]] - [[下前頭回]] [[三角部]]
|-
* [[Brodmann area 46|ブロードマン46野]] - [[前頭前野背外側部]]
| Etravirine || [https://clinicaltrials.gov/ct2/show/NCT04273165 NCT04273165] || 2020－ || イタリア || Friedreich Ataxia || 2 || 開始前
* [[Brodmann area 47|ブロードマン47野]] - [[下前頭前野]]
|-
* [[Brodmann area 48|ブロードマン48野]] - [[Brodmann_area_48|Retrosubicular area]] (a small part of the medial surface of the temporal lobe)
| RT001 || [https://www.clinicaltrials.gov/ct2/show/NCT04102501 NCT04102501] || 2019- || 米国 || Friedreich Ataxia || 3 || 進行中
* [[Brodmann area 49|ブロードマン49野]] - [[Parasubiculum]] area in a rodent
|-
* [[Brodmann area 52|ブロードマン52野]] - [[Parainsular_area_52|Parainsular]] area (at the junction of the temporal lobe and the [[Insular cortex|insula]])
| Resveratrol || [https://clinicaltrials.gov/ct2/show/NCT03933163 NCT03933163] || 2019- || 米国 || Friedreich Ataxia || 2 || 進行中
(*) Area only found in non-human [[primate]]s.
|-
 
| MIN-102 || [https://clinicaltrials.gov/ct2/show/NCT03917225 NCT03917225] || 2019－ || EU || Friedreich Ataxia || 2 || リクルート終了
Some of the original Brodmann areas have been subdivided further, e.g., "23a" and "23b".<ref>{{Cite journal
|-
| author = Brent A. Vogt, [[Deepak Pandya|Deepak N. Pandya]], Douglas L. Rosene
| gamma interferon || [https://clinicaltrials.gov/ct2/show/NCT03888664 NCT03888664]<br>[https://clinicaltrials.gov/ct2/show/NCT02797080 NCT02797080]<br>[https://clinicaltrials.gov/ct2/show/NCT02593773 NCT02593773]<br>[https://www.clinicaltrials.gov/ct2/show/NCT01965327 NCT01965327]||  ||  || Friedreich Ataxia || 2、3 ||  
| title = Cingulate cortex of the rhesus monkey: I. Cytoarchitecture and thalamic afferents
|-
| journal = The Journal of Comparative Neurology
| Nicotinamide || [https://clinicaltrials.gov/ct2/show/NCT03761511 NCT03761511] || 2018- || EU || Friedreich Ataxia || 2 || 進行中
| volume = 262
|-
| issue = 2
| TAK-831 || [https://www.clinicaltrials.gov/ct2/show/NCT03214588 NCT03214588] || 2017-2019 || 米国 || Friedreich Ataxia || 2 || 有効性なし
| pages = 256&ndash;270
|-
| month = August
| Rosuvastatin || [https://www.clinicaltrials.gov/ct2/show/NCT02705547 NCT02705547] || 2016-2018 || 米国 || Friedreich Ataxia || 1 || リクルート終了
| year = 1987
|-
| doi = 10.1002/cne.902620207
| (+)-Epicatechin || [https://clinicaltrials.gov/ct2/show/NCT02660112 NCT02660112] || 2016-2019 || 米国 || Friedreich Ataxia || 2 || 有効性なし
| pmid = 3624554
|-
}}</ref>
| Methylprednisolone || [https://www.clinicaltrials.gov/ct2/show/NCT02424435 NCT02424435] || 2015-2020 || 米国 || Friedreich Ataxia || 1 || リクルート終了
 
|-
=== Clickable map: Lateral Surface ===
| EPI-743(alpha-tocotrienol quinone) || [https://clinicaltrials.gov/ct2/show/NCT01962363 NCT01962363] || 2013-2016 || 米国 || Friedreich's Ataxia with Point Mutations || 2 || [https://n.neurology.org/content/86/16_Supplement/P5.388 効果あり]
<imagemap>
|-
Image:Gray726-Brodman.png|Image mapped [[Brodmann Areas]]. Clicking on an area in the picture causes the browser to load the appropriate article.|480px 
| Omaveloxolone || [https://clinicaltrials.gov/ct2/show/NCT02255435 NCT02255435] || 2014- || 米国 || Friedreich Ataxia || 2 || リクルート停止
rect 509 186 596 236 [[Brodmann areas 3, 1 and 2|Areas 3, 1 & 2 - Primary Somatosensory Cortex]]
|-
rect 474 122 524 172 [[Brodmann area 4|Area 4 - Primary Motor Cortex]]
| Acetyl-L-Carnitine || [https://www.clinicaltrials.gov/ct2/show/NCT01921868 NCT01921868] || 2013-2017 || 米国 || Friedreich Ataxia || Not Applicable || 結果未報告
rect 602 143 652 193 [[Brodmann area 5|Area 5 - Somatosensory Association Cortex]]
|-
rect 378 162 428 212 [[Brodmann area 6|Area 6 - Premotor cortex and Supplementary Motor Cortex (Secondary Motor Cortex)(Supplementary motor area]]
| VP 20629 || [https://clinicaltrials.gov/ct2/show/NCT01898884 NCT01898884] || 2013-2016 || 米国 || Friedreich Ataxia || 1 || リクルート終了
rect 692 178 742 228 [[Brodmann area 7|Area 7 - Somatosensory Association Cortex]]
|-
rect 259 107 309 157 [[Brodmann area 8|Area 8 - Includes Frontal eye fields]]
| EPI-743 || [https://clinicaltrials.gov/ct2/show/NCT01728064 NCT01728064] || 2012-2015 || 米国 || Friedreich Ataxia || 2 || 有効性なし
rect 137 162 188 212 [[Brodmann area 9|Area 9- Dorsolateral prefrontal cortex]]
|-
rect 31  330 81  380 [[Brodmann area 10|Area 10 - Anterior prefrontal cortex]]
| Bupropion and Citalopram || [https://clinicaltrials.gov/ct2/show/NCT01716221 NCT01716221] || 2012-2016 || 米国 || Friedreich Ataxia || 4 || 終了
rect 65  427 116 477 [[Brodmann area 11|Area 11 - Orbitofrontal area]]
|-
rect 892 459 942 509 [[Brodmann area 17|Area 17 - Primary visual cortex (V1)]]
| Resveratrol || [https://clinicaltrials.gov/ct2/show/NCT01339884 NCT01339884] || 2011-2014 || オーストラリア || Friedreich Ataxia || 1,2 || 終了
rect 834 427 885 477 [[Brodmann area 18|Area 18 - Secondary visual cortex (V2)]]
|-
rect 770 385 821 435 [[Brodmann area 19|Area 19 - Associative visual cortex (V3)]]
| Idebenone || [https://clinicaltrials.gov/ct2/show/NCT01303406 NCT01303406] || 2011-2016 || EU || Friedreich Ataxia || 3 || 有効性なし
rect 427 554 477 604 [[Brodmann area 20|Area 20 - Inferior temporal gyrus]]
|-
rect 474 491 524 541 [[Brodmann area 21|Area 21 - Middle temporal gyrus]]
| A0001(alpha-tocopherolquinone) || [https://clinicaltrials.gov/ct2/show/NCT01035671 NCT01035671] || 2009-2011 || 米国 || Friedreich Ataxia || 2 || [https://onlinelibrary.wiley.com/doi/full/10.1002/mds.25058 容量依存性にFRDA評価スケール改善]
rect 635 417 686 467 [[Brodmann area 22|Area 22 - Superior temporal gyrus]]
|-
 
| Erythropoietin || [https://clinicaltrials.gov/ct2/show/NCT01016366 NCT01016366] || 2009-2016 || EU || Friedreich Ataxia || 2 || 有効性なし
rect 673 484 723 534 [[Brodmann area 37|Area 37 - Fusiform gyrus]]
|-
rect 250 505 301 555 [[Brodmann area 38|Area 38 - Temporopolar area]]
| idebenone || [https://clinicaltrials.gov/ct2/show/NCT00993967 NCT00993967] || 2009-2016 || EU || Friedreich Ataxia || 3 || 認容性を副作用の確認
rect 706 307 757 357 [[Brodmann area 39|Area 39 - Angular gyrus]]
|-
rect 571 315 622 365 [[Brodmann area 40|Area 40 - Supramarginal gyrus]]
| deferiprone || [https://clinicaltrials.gov/ct2/show/NCT00530127 NCT00530127] || 2007-2009 || EU || Friedreich Ataxia || 1,2 || [https://onlinelibrary.wiley.com/doi/full/10.1002/ana.24248 非重症例で進行抑制の可能性(+)]
rect 536 394 587 444 [[Brodmann area 41 & 42|Area 41- Primary and Auditory Association Cortex]]
|-
rect 589 411 634 461 [[Brodmann area 41 & 42|Area 42 - Primary and Auditory Association Cortex]]
| EGb 761 || [https://clinicaltrials.gov/ct2/show/NCT00824512 NCT00824512] || 209-2013 || フランス || Friedreich Ataxia || 2 || 有効性なし
rect 416 368 467 418 [[Brodmann area 43|Area 43 - Primary gustatory cortex]]
|-
rect 282 353 333 403 [[Brodmann area 44|Area 44 - pars opercularis, part of Broca's area]]
| pioglitazone || [https://clinicaltrials.gov/ct2/show/NCT00811681 NCT00811681] || 2008-2013 || フランス || Friedreich Ataxia || 3 || 終了
rect 219 378 270 428 [[Brodmann area 45|Area 45 - pars triangularis, Broca's area]]
|-
rect 144 257 195 307 [[Brodmann area 46|Area 46 - Dorsolateral prefrontal cortex]]
| varenicline || [https://www.clinicaltrials.gov/ct2/show/NCT00803868 NCT00803868] || 2008-2010 || 米国 || Friedreich Ataxia || 2，3 || 途中で中止
rect 145 410 196 460 [[Brodmann area 47|Area 47 - Inferior prefontal gyrus]]
|-
rect 958 718 960 720 [http://www.image-maps.com/index.php?aff=mapped_users_4201105031226273 Image Map]
| Triheptanoin || [https://clinicaltrials.gov/ct2/show/NCT04513002 NCT04513002] || 2020- || オーストラリア || Ataxia Telangiectasia || 2 || リクルート開始前
desc bottom-left
|-
</imagemap>
| vitamin B3 || [https://clinicaltrials.gov/ct2/show/NCT03962114 NCT03962114] || 2019- || オランダ || Ataxia Telangiectasia || 2 || リクルート中
 
|-
=== Clickable map: Medial Surface ===
| N-Acetyl-L-Leucine || [https://clinicaltrials.gov/ct2/show/NCT03759678 NCT03759678] || 2018- || 米，英，独 || Ataxia Telangiectasia || 2 || リクルート中
 
|-
<imagemap>
| Metformin，Pioglitazone || [https://clinicaltrials.gov/ct2/show/NCT02733679 NCT02733679] || 2016-2019 || 英国 || Ataxia Telangiectasia || 4 || 終了
Image:Gray727-Brodman.png|Image mapped [[Brodmann Areas]]. Clicking on an area in the picture causes the browser to load the appropriate article.|480px 
|-
rect 509 186 596 236 [[Brodmann areas 3, 1 and 2|Areas 3, 1 & 2 - Primary Somatosensory Cortex]]
| Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate || [https://clinicaltrials.gov/ct2/show/NCT01052623 NCT01052623] || 2010-2011 || ドイツ || Ataxia Telangiectasia || 4 || 結果？
rect 442 99 492 149  [[brodmann area 4|area 4 - primary motor cortex]]
|-
rect 538 162 588 212 [[Brodmann area 5|Area 5 - Somatosensory Association Cortex]]
| amantadine sulphate || [https://clinicaltrials.gov/ct2/show/NCT00950196 NCT00950196] || 2009-2011 || イスラエル || Ataxia Telangiectasia || 4 || [https://journals.sagepub.com/doi/10.1177/0883073812441999 運動症状を改善]
rect 306 122 356 172 [[Brodmann area 6|Area 6 - Premotor cortex and Supplementary Motor Cortex (Secondary Motor Cortex)(Supplementary motor area]]
|-
rect 714 155 764 205 [[Brodmann area 7|Area 7 - Somatosensory Association Cortex]]
| Baclofen || [https://clinicaltrials.gov/ct2/show/NCT00640003 NCT00640003] || 2008-2011 || 米国 || Ataxia Telangiectasia || 1 || 結果？
rect 193 155 243 205 [[Brodmann area 8|Area 8 - Includes Frontal eye fields]]
|}
rect 106 211 156 261 [[Brodmann area 9|Area 9- Dorsolateral prefrontal cortex]]
rect 35 323 85 373  [[Brodmann area 10|Area 10 - Anterior prefrontal cortex]]
rect 74 441 124 491  [[Brodmann area 11|Area 11 - Orbitofrontal area]]
rect 162 404 212 454 [[Brodmann area 12|Area 12 -Orbitofrontal area]]
rect 819 378 869 428 [[Brodmann area 17|Area 17 - Primary visual cortex (V1)]]
rect 761 428 811 478 [[Brodmann area 18|Area 18 - Secondary visual cortex (V2)]]
rect 697 467 747 517 [[Brodmann area 19|Area 19 - Associative visual cortex (V3)]]
rect 810 233 860 283 [[Brodmann area 19|Area 19 - Associative visual cortex (V3)]]
rect 860 308 910 358 [[Brodmann area 18|Area 18 - Secondary visual cortex (V2)]]
rect 563 289 613 339 [[Brodmann area 23|Area 23 - Ventral Posterior cingulate cortex]]
rect 314 210 364 260 [[Brodmann area 24|Area 24 - Ventral Anterior cingulate cortex]]
rect 227 434 277 484 [[Brodmann area 25|Area 25 - Subgenual cortex (part of the Ventromedial prefontal cortex)]]
rect 512 355 562 405 [[Brodmann area 26|Area 26 - Ectosplenial portion of the retrosplenial region of the cerebral cortex]]
rect 377 448 427 498 [[Brodmann area 27|Area 27 - Piriform cortex]]
rect 314 489 364 539 [[Brodmann area 28|Area 28 - Posterior Entorhinal Cortex]]
rect 571 371 621 421 [[Brodmann area 29|Area 29 - Retrosplenial cingulate cortex]]
rect 532 419 582 469 [[Brodmann area 30|Area 30 - Part of cingulate cortex]]
rect 632 264 682 314 [[Brodmann area 31|Area 31 - Dorsal Posterior cingulate cortex]]
rect 138 330 188 380 [[Brodmann area 32|Area 32 - Dorsal anterior cingulate cortex]]
rect 234 290 284 340 [[Brodmann area 33|Area 33 - Part of anterior cingulate cortex]]
rect 305 435 355 485 [[Brodmann area 34|Area 34 - Anterior Entorhinal Cortex (on the Parahippocampal gyrus)]]
rect 448 450 498 500 [[Brodmann area 35|Area 35 - Perirhinal cortex (on the Parahippocampal gyrus)]]
rect 448 507 498 557 [[Brodmann area 20|Area 20 - Inferior temporal gyrus]]
rect 585 482 635 532 [[Brodmann area 37|Area 37 - Fusiform gyrus]]
rect 559 100 648 150 [[Brodmann areas 3, 1 and 2|Areas 3, 1 & 2 - Primary Somatosensory Cortex]]
rect 265 532 318 582 [[Brodmann area 38|Area 38 - Temporopolar area]]
rect 958 718 960 720 [http://www.image-maps.com/index.php?aff=mapped_users_1201105031640502 Image Map]
desc bottom-left
</imagemap>
<references/>

2021年2月17日 (水) 21:27時点における最新版

化合物 ClinicalTrials.gov Identifier 年 国 対象疾患 Phase 結果
Taltirelin Hydrate NCT04107740 2019- 韓国 SCD全般 4 現在進行中
KPS-0373(Rovatirelin) NCT01970098 2013-2015 日本 軽度～中等度のSCD 3 部分的に有効
Riluzole NCT03347344 2018-2019 フランス SCA2 3 不明
Transcranial Magnetic Stimulation NCT01975909 2013-2016 米国 genetically-confirmed SCA Not Applicable 有効性なし
Lithium Carbonate NCT00683943 2008－2010 米国 SCA1 1
Intravenous Immune Globulin NCT02287064 2015－2016 米国 SCA types 1, 2, 3, 6, 10, or 11 1 まだ発表なし
Oral Trehalose NCT04399265 2020ー- マレーシア Genetically confirmed SCA 3 Not Applicable 進行中
Varenicline (Chantix®) NCT00992771 2009－2012 米国 SCA3 2 有効
Umbilical Cord Mesenchymal Stem Cells NCT03378414 2017－ 中国 SCA1,2,4,6 2 詳細不明
Troriluzole NCT03701399 2018－ 米国 SCA1,2,3,6,7,8,10 2，3 進行中
Sodium Phenylbutyrate NCT01096095 2010－2012 ブラジル SCA3 2 中止
Dalfampridine NCT01811706 2013－2015 米国 SCA1,2,3,6 Not Applicable 有効性なし
CAD-1883 NCT04301284 2020－ 米国 SCA1,2,3,6,7,10,17 2 延期(COVID-19のため
Docosahexaenoic Acid (DHA) NCT03109626 2015－2018 イタリア SCA38 Not Applicable 有効
Stemchymal® NCT02540655 2015－ 台湾 SCA2,3 2 不明
Intravenous Cabaletta NCT02147886 2014-2016 イスラエル SCA3 2 結果？
Coenzyme Q10 NCT00957216 2009－2018 米国 弧発性SCD 1 結果？
BHV-4157 NCT03408080 2018－ 米国 SCA1,2,3,6 3 エントリー中止中
Vatiquinone NCT04577352 2020－ 米国 Friedreich Ataxia 2，3 開始前
CTI-1601 NCT04519567 2020－ 米国 Friedreich Ataxia 1 開始前
Etravirine NCT04273165 2020－ イタリア Friedreich Ataxia 2 開始前
RT001 NCT04102501 2019- 米国 Friedreich Ataxia 3 進行中
Resveratrol NCT03933163 2019- 米国 Friedreich Ataxia 2 進行中
MIN-102 NCT03917225 2019－ EU Friedreich Ataxia 2 リクルート終了
gamma interferon NCT03888664
NCT02797080
NCT02593773
NCT01965327		 Friedreich Ataxia 2、3
Nicotinamide NCT03761511 2018- EU Friedreich Ataxia 2 進行中
TAK-831 NCT03214588 2017-2019 米国 Friedreich Ataxia 2 有効性なし
Rosuvastatin NCT02705547 2016-2018 米国 Friedreich Ataxia 1 リクルート終了
(+)-Epicatechin NCT02660112 2016-2019 米国 Friedreich Ataxia 2 有効性なし
Methylprednisolone NCT02424435 2015-2020 米国 Friedreich Ataxia 1 リクルート終了
EPI-743(alpha-tocotrienol quinone) NCT01962363 2013-2016 米国 Friedreich's Ataxia with Point Mutations 2 効果あり
Omaveloxolone NCT02255435 2014- 米国 Friedreich Ataxia 2 リクルート停止
Acetyl-L-Carnitine NCT01921868 2013-2017 米国 Friedreich Ataxia Not Applicable 結果未報告
VP 20629 NCT01898884 2013-2016 米国 Friedreich Ataxia 1 リクルート終了
EPI-743 NCT01728064 2012-2015 米国 Friedreich Ataxia 2 有効性なし
Bupropion and Citalopram NCT01716221 2012-2016 米国 Friedreich Ataxia 4 終了
Resveratrol NCT01339884 2011-2014 オーストラリア Friedreich Ataxia 1,2 終了
Idebenone NCT01303406 2011-2016 EU Friedreich Ataxia 3 有効性なし
A0001(alpha-tocopherolquinone) NCT01035671 2009-2011 米国 Friedreich Ataxia 2 容量依存性にFRDA評価スケール改善
Erythropoietin NCT01016366 2009-2016 EU Friedreich Ataxia 2 有効性なし
idebenone NCT00993967 2009-2016 EU Friedreich Ataxia 3 認容性を副作用の確認
deferiprone NCT00530127 2007-2009 EU Friedreich Ataxia 1,2 非重症例で進行抑制の可能性(+)
EGb 761 NCT00824512 209-2013 フランス Friedreich Ataxia 2 有効性なし
pioglitazone NCT00811681 2008-2013 フランス Friedreich Ataxia 3 終了
varenicline NCT00803868 2008-2010 米国 Friedreich Ataxia 2，3 途中で中止
Triheptanoin NCT04513002 2020- オーストラリア Ataxia Telangiectasia 2 リクルート開始前
vitamin B3 NCT03962114 2019- オランダ Ataxia Telangiectasia 2 リクルート中
N-Acetyl-L-Leucine NCT03759678 2018- 米，英，独 Ataxia Telangiectasia 2 リクルート中
Metformin，Pioglitazone NCT02733679 2016-2019 英国 Ataxia Telangiectasia 4 終了
Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate NCT01052623 2010-2011 ドイツ Ataxia Telangiectasia 4 結果？
amantadine sulphate NCT00950196 2009-2011 イスラエル Ataxia Telangiectasia 4 運動症状を改善
Baclofen NCT00640003 2008-2011 米国 Ataxia Telangiectasia 1 結果？
「https://bsd.neuroinf.jp/w/index.php?title=テスト&oldid=45878」から取得